- Nelson Advisors LLP
- About Us
- Contact Us
- Message Us
- Meet Us
- FAQ's
- Mission and Vision
- Expertise
- Services
- Lower to Mid Market
- Corporate Divestitures
- Healthcare AI
- Digital Health
- Transactions
- Behaviour Change
- App Platform Data AI
- Research
- University Business Schools
- Thought Leadership
- Careers
- Lloyd G Price
- Press and Awards
- Blog
- Insights
- Newsletter
Nelson Advisors: Creating Liquidity From Struggling European HealthTech, MedTech, Health AI Portfolio Companies
NA
Every European health fund raised between 2019 and 2022 now holds companies that are alive, off plan and unlikely to raise another priced round. They are not the winners that will return the fund, and they are not the write-offs that have already been taken. They sit in the middle: a CE-marked device with slow hospital uptake, a digital therapeutic with a reimbursement code in one country and nothing elsewhere, a health AI company whose models are good but whose NHS or German sick-fund sales cycle has eaten three years of runway.
These companies absorb a disproportionate share of partner time, reserve capital and LP patience. Left alone, most of them drift towards a down round nobody wants to lead or a quiet insolvency that returns nothing. Yet many of them hold real, monetisable assets: regulatory clearances, clinical evidence, structured health data, signed hospital contracts, specialist teams and, occasionally, a profitable core business hidden inside a growth story that no longer works.
This article is about the gap between those two outcomes. It sets out the practical routes a general partner can take to turn a struggling European healthtech, medtech or health AI company into cash, carried value or at least a clean exit, and how to decide which route fits which company. None of these routes produces a fund-returning multiple. All of them beat the default, which is to hope and wait.